Relmada Therapeutics, Inc. RLMD APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition
APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s apic, share-based payment arrangement, option, increase for cost recognition.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s APIC, share-based payment arrangement, option, increase for cost recognition?
- Relmada Therapeutics, Inc. (RLMD) reported APIC, share-based payment arrangement, option, increase for cost recognition of $956.19K in Q1 2026.
- How has Relmada Therapeutics, Inc.'s APIC, share-based payment arrangement, option, increase for cost recognition changed year-over-year?
- Relmada Therapeutics, Inc.'s APIC, share-based payment arrangement, option, increase for cost recognition decreased by 73.2% year-over-year, from $3.57M to $956.19K.
- What is the long-term trend for Relmada Therapeutics, Inc.'s APIC, share-based payment arrangement, option, increase for cost recognition?
- Over 3 years (2022 to 2025), Relmada Therapeutics, Inc.'s APIC, share-based payment arrangement, option, increase for cost recognition has grown at a -32.0% compound annual growth rate (CAGR), from $44.19M to $13.91M.
- What does APIC, share-based payment arrangement, option, increase for cost recognition mean?
- Represents the non-cash expense recognized for share-based payment awards over the requisite service period of employees. This metric reflects the accounting cost of equity-based compensation plans and is essential for understanding the dilution and compensation structure of the company.